Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma

Fig. 2

CREB5 regulates mitochondrial apoptosis in parent and cisplatin-resistant cells. A, B MTT assay was used to analyze the relationship between CREB5 expression and proliferation in parent and cisplatin-resistant cells. C, D The relationship between CREB5 expression and the ability to form colonies was analyzed in parent and cisplatin-resistant cells. E Flow cytometry was used to analyze the effect of CREB5 overexpression on the basal and cisplatin-induced (5 μM for 48 h) apoptosis percentage in HN4 and HN30 cells. F Flow cytometry was used to analyze the effect of CREB5 knockdown on the basal and cisplatin-induced (20 μM for 48 h) apoptosis percentage in HN4/DDP and HN30/DDP cells. G The flow chart of the mitochondrial apoptotic pathway. H Immunoblotting was used to analyze the effect of CREB5 knockdown or overexpression on the mitochondrial apoptosis pathway in cisplatin-resistant and parent cells, respectively. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us